Spero Therapeutics Inc (SPRO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $58.26M
Last updated: Nov 17, 2026 at 4:11 PM ET
Spero Therapeutics Inc (SPRO) Statistics
Spero Therapeutics (SPRO) has a market cap of $58.26M. It holds $107.93M more cash than debt, 185.26% of its market cap. It kept -71.02% of revenue as net income over the last 12 months.
Total Valuation
| Market Cap | $58.26M |
|---|---|
| Latest price (Nov 17, 2026) | $0.90 |
Key Dates
The next earnings report is expected on Mar 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 1.3x and 67.2x.
| P/E Ratio | 10.6x |
|---|---|
| P/S Ratio | 1.3x |
| Forward P/S | 194.2x |
| P/B Ratio | 67.2x |
Price Statistics
The stock is down 62.60% over 52 weeks and trades 20.35% below its 50-day average.
| Beta (1Y) | 1.53 |
|---|---|
| 52-Week Change | -62.60% |
| 1-Month Change | -19.53% |
| 3-Month Change | -26.72% |
| 6-Month Change | -65.20% |
| 5-Year Change | -93.96% |
| Total Return (1Y) | -62.60% |
| Total Return (3Y CAGR) | -8.84% |
| Total Return (5Y CAGR) | -44.04% |
| Max Drawdown (1Y) | -69.75% |
| Max Drawdown (3Y) | -70.35% |
| Sharpe Ratio (1Y) | -1.54 |
| Correlation with SPY (1Y) | 0.32 |
| 50-Day Average | $1.13 |
| 200-Day Average | $1.90 |
| 52-Week Range | $0.90 to $3.08 |
| RSI (14 Days) | 31.6 |
| Average Volume (20 Days) | 338.16K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.92x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 1.92x |
|---|---|
| Quick Ratio | 1.92x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -3778.87% over the last 12 months, against a 5-year average of -55.12%.
| Return on Equity (ROE) | -3778.87% |
|---|---|
| Return on Assets (ROA) | -26.82% |
| Return on Capital Employed (ROCE) | -52.72% |
| ROE (5Y Average) | -55.12% |
| ROA (5Y Average) | -25.35% |
| ROIC (5Y Average) | 10.38% |
| Asset Turnover | 0.51x |
Scores
SPRO has an Altman Z-Score of -6.12, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -6.12 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $41.55M over the last 12 months is up 2.48% from the 12 months before.
| Revenue | $41.55M |
|---|---|
| Revenue Growth (YoY) | +2.48% |
| Gross Profit | $41.55M |
| Operating Income | -$27.97M |
| Pretax Income | -$29.25M |
| Net Income | -$29.51M |
| EBIT | -$27.98M |
| Reported EPS (TTM) | $0.09 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 0.71% of the $110.03M in total assets.
| Cash and Equivalents | $107.93M |
|---|---|
| Total Debt | $0 |
| Net Cash | $107.93M |
| Net Cash Per Share | $1.85 |
| Working Capital | $52.27M |
| Shareholder Equity | $781.00K |
| Book Value Per Share | $0.01 |
| Total Assets | $110.03M |
| Total Liabilities | $109.25M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$40.45M |
|---|---|
| FCF Per Share | -$0.69 |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -67.31%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -67.31% |
| Pretax Margin | -70.39% |
| Net Margin | -71.02% |
| EBIT Margin | -67.32% |
Growth
Revenue grew 7.68% a year over 3 years.
| Revenue Growth (3Y CAGR) | +7.68% |
|---|---|
| Revenue Growth (5Y CAGR) | +48.25% |
| Book Value Per Share Growth (2Y CAGR) | -29.72% |
| Tangible Book Per Share Growth (2Y CAGR) | -29.72% |
Dividends and Yields
SPRO does not pay a dividend.
| Earnings Yield | 9.43% |
|---|---|
| Shareholder Yield | 0.00% |
Peer Position
Against 5 similar companies, SPRO has the 5th highest P/S.
P/S RatioPeer median 2.9x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -48.86%
| P/S Ratio | 1.3x vs 2.9x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +2.48% vs -48.86% median |
Analyst Forecast
Consensus estimates put revenue growth at -99.55% a year over the next fiscal year.
| Revenue Growth Forecast (1Y CAGR) | -99.55% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About SPRO
What is SPRO's market cap?
Spero Therapeutics has a market cap of $58.26M.
What is SPRO's P/E ratio?
Spero Therapeutics has a trailing P/E ratio of 10.6x.
How many shares of SPRO are outstanding?
Spero Therapeutics has 58.23M shares outstanding. The count is up 3.46% from a year earlier.
Does SPRO pay a dividend?
No. Spero Therapeutics does not pay a dividend.
How much debt does SPRO have?
Spero Therapeutics has $0 of total debt and $107.93M of cash and equivalents, a net cash position of $107.93M.
SPRO pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts